Myasthenia Gravis Market

Myasthenia Gravis Market (Treatment- Drug Treatment (Cholinesterase Inhibitors, Monoclonal Antibodies, and Chronic Immunomodulators) and Rapid Immunotherapies (Plasmapheresis, Intravenous Immunoglobulin (IVlg), and Thymectomy)) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

  • Rep Id : TMRGL26105
  • Published On : Dec 2017
  • No. of Pages : 161
  • Category : Pharmaceutical

Section – 1 Preface 
1.1 Report Scope and Market Segmentation 
1.2 Research Highlights

Section – 2 Assumptions and Research Methodology 
2.1 Assumptions
2.2 Acronyms Used
2.3 Research Methodology

Section – 3 Executive Summary
3.1 Global Myasthenia Gravis Market Snapshot

Section – 4 Market Overview
4.1. Market Overview
4.2. Key Industry Events 
4.3. Global Myasthenia Gravis Market Size (US$ Mn) Forecast, 2015-2025 
4.5. Global Myasthenia Gravis Market Outlook
4.6. Porter's Five Forces 

Section – 5 Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
       5.2.1. Rise in prevalence of autoimmune disorders
       5.2.2. Newer approved therapies
       5.2.3. Strong pipeline in myasthenia gravis treatment
       5.2.4. Increase in health care spending and improving health care infrastructure
5.3. Restraints
       5.3.1. Limited availability of FDA approved drugs
       5.3.2. Expensive treatment options
       5.3.3. Chronic side effects
5.4 Opportunities
5.5. Myasthenia Gravis Market – Market Trend
5.6. Regulatory Scenario 
5.7. Myasthenia Gravis Pipeline Analysis – Snapshot 

Section – 6 Global Myasthenia Gravis Market Analysis, by Treatment
6.1. Key Findings
6.2. Introduction – Product Definition 
6.3. Global Myasthenia Gravis Market Value Share Analysis, by Treatment
6.4. Global Myasthenia Gravis Market Forecast, by Treatment
6.5. Global Myasthenia Gravis Market Forecast, by Treatment – Drug Treatment
6.6. Global Myasthenia Gravis Market Forecast, by Treatment – Rapid Immunotherapies
6.7. Global Myasthenia Gravis Market Analysis, by Treatment
6.8. Global Myasthenia Gravis Market Analysis, by Rapid Immunotherapies
6.9. Global Myasthenia Gravis Market Attractiveness Analysis, by Treatment

Section – 7 Myasthenia Gravis Market Analysis, by Region
7.1. Key Findings
7.2. Geographical Scenario
7.3. Myasthenia Gravis Market Value Share Analysis, by Region
7.4. Global Myasthenia Gravis Treatment Market Forecast, by Region 
7.5. Myasthenia Gravis Market Attractiveness Analysis, by Region

Section – 8 North America Myasthenia Gravis Market Analysis
8.1. Key Findings
8.2. Market Overview
8.3. North America Myasthenia Gravis Market Value Share Analysis, by Country
8.4. North America Myasthenia Gravis Market Forecast, by Country
8.5. North America Myasthenia Gravis Market Value Share Analysis, by Treatment 
8.6. North America Myasthenia Gravis Market Forecast, by Treatment
8.7. North America Myasthenia Gravis Market Forecast, by Drug Treatment
8.8. North America Myasthenia Gravis Market Forecast, by Rapid Immunotherapies

Section – 9 Europe Myasthenia Gravis Market Analysis
9.1. Key Findings
9.2. Market Overview
9.3. Europe Myasthenia Gravis Market Value Share Analysis, by Country
9.4. Europe Myasthenia Gravis Market Forecast, by Country
9.5. Europe Myasthenia Gravis Market Value Share Analysis, by Treatment
9.6. Europe Myasthenia Gravis Market Forecast, by Treatment
9.7. Europe Myasthenia Gravis Market Forecast, by Treatment – Drug Treatment
9.8. Europe Myasthenia Gravis Market Forecast, by Treatment – Rapid Immunotherapies

Section – 10 Asia Pacific Myasthenia Gravis Market Analysis
10.1. Key Findings
10.2. Market Overview
10.3. Asia Pacific Myasthenia Gravis Market Value Share Analysis, by Country
10.4. Asia Pacific Myasthenia Gravis Market Forecast, by Country
10.5. Asia Pacific Myasthenia Gravis Market Value Share Analysis, by Treatment 
10.6. Asia Pacific Myasthenia Gravis Market Forecast, by Treatment
10.7. Asia Pacific Myasthenia Gravis Market Forecast, by Drug Treatment
10.8. Asia Pacific Myasthenia Gravis Market Forecast, by Rapid Immunotherapies

Section – 11 Latin America Myasthenia Gravis Market Analysis
11.1. Key Findings
11.2. Market Overview
11.3. Latin America Myasthenia Gravis Market Value Share Analysis, by Country
11.4. Latin America Myasthenia Gravis Market Forecast, by Country
11.5. Latin America Myasthenia Gravis Market Value Share Analysis, by Treatment 
11.6. Latin America Myasthenia Gravis Market Forecast, by Treatment
11.7. Latin America Myasthenia Gravis Market Forecast, by Drug Treatment
11.8. Latin America Myasthenia Gravis Market Forecast, by Rapid Immunotherapies

Section – 12 Middle East & Africa Myasthenia Gravis Market Analysis
12.1. Key Findings
12.2. Market Overview
12.3. Middle East & Africa Myasthenia Gravis Market Value Share Analysis, by Country
12.4. Middle East & Africa Myasthenia Gravis Market Forecast, by Country
12.5. Middle East & Africa Myasthenia Gravis Market Value Share Analysis, by Treatment
12.6. Middle East & Africa Myasthenia Gravis Market Forecast, by Treatment
12.7. Middle East & Africa Myasthenia Gravis Market Forecast, by Drug Treatment
12.8. Middle East & Africa Myasthenia Gravis Market Forecast, by Rapid Immunotherapies

Section -13 Competition Landscape
13.1. Myasthenia Gravis Market Heat Map Analysis by Company, 2016
13.2. Competition Matrix
13.3. Company Profiles
       13.3.1 Alexion Pharmaceutical Inc.
                13.3.1.1 Company Details
                13.3.1.2 Business Overview
                13.3.1.3 Financial Overview
                13.3.1.4 Strategic Overview
                13.3.1.5 SWOT Analysis
       13.3.2 Avadel Pharmaceuticals, PLC. (Flamel Technologies)
                13.3.2.1 Company Details
                13.3.2.2 Business Overview
                13.3.2.3 Financial Overview
                13.3.2.4 Strategic Overview
                13.3.2.5 SWOT Analysis
       13.3.3. CSL Behring
                13.3.3.1 Company Details
                13.3.3.2 Business Overview
                13.3.3.3 Financial Overview
                13.3.3.4 Strategic Overview
                13.3.3.5 SWOT Analysis
       13.3.4. Grifols, S.A.
                13.3.4.1 Company Details
                13.3.4.2 Business Overview
                13.3.4.3 Financial Overview
                13.3.4.4 Strategic Overview
                13.3.4.5 SWOT Analysis
       13.3.5. Baxter International, Inc. 
                13.3.5.1 Company Details
                13.3.5.2 Business Overview
                13.3.5.3 Financial Overview
                13.3.5.4 Strategic Overview
                13.3.5.5 SWOT Analysis
       13.3.6. Shire plc 
                13.3.6.1 Company Details
                13.3.6.2 Business Overview
                13.3.6.3 Financial Overview
                13.3.6.4 Strategic Overview
                10.3.6.5 SWOT Analysis
       13.3.7. Novartis AG 
                13.3.7.1 Company Details
                13.3.7.2 Business Overview
                13.3.7.3 Financial Overview
                13.3.7.4 Strategic Overview
                13.3.7.5 SWOT Analysis
       13.3.8 F. Hoffmann-La Roche AG
                13.3.8.1 Company Details
                13.3.8.2 Business Overview
                13.3.8.3 Financial Overview
                13.3.8.4 Strategic Overview
                13.3.8.5 SWOT Analysis
       13.3.9. Takeda Pharmaceutical Company Limited 
                13.3.9.1 Company Details
                13.3.9.2 Business Overview
                13.3.9.3 Financial Overview
                13.3.9.4 Strategic Overview
                13.3.9.5 SWOT Analysis
       13.3.10. Valeant Pharmaceuticals International, Inc.  
                13.3.10.1 Company Details
                13.3.10.2 Business Overview
                13.3.10.3 Financial Overview
                13.3.10.4 Strategic Overview
                13.3.10.5 SWOT Analysis

List of Tables

Table 01: Global Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
Table 02: Global Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment – Drug Treatment, 2015–2025
Table 03: Global Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment – Rapid Immunotherapies, 2015–2025
Table 04: Global Myasthenia Gravis Market Size (US$ Mn) Forecast, by Region, 2015–2024
Table 05: North America Myasthenia Gravis Market Size (US$ Mn) and Forecast, by Country, 2015–2025
Table 06: North America Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
Table 07: North America Myasthenia Gravis Market Size (US$ Mn) Forecast, by Drug Treatment, 2015–2025
Table 08: North America Myasthenia Gravis Market Size (US$ Mn) Forecast, by Rapid Immunotherapies, 2015–2025
Table 09: Europe Myasthenia Gravis Market Size (US$ Mn) Forecast, by Country, 2015–2025
Table 10: Europe Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
Table 11: Europe Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment – Drug Treatment, 2015–2025
Table 12: Europe Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment – Rapid Immunotherapies, 2015–2025
Table 13: Asia Pacific Myasthenia Gravis Market Size (US$ Mn) and Forecast, by Country, 2015–2025
Table 13: Asia Pacific Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
Table 14: Asia Pacific Myasthenia Gravis Market Size (US$ Mn) Forecast, by Drug Treatment, 2015–2025
Table 15: Asia Pacific Myasthenia Gravis Market Size (US$ Mn) Forecast, by Rapid Immunotherapies, 2015–2025
Table 16: Latin America Myasthenia Gravis Market Size (US$ Mn) and Forecast, by Country/Sub-region, 2015–2025
Table 17: Latin America Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
Table 18: Latin America Myasthenia Gravis Market Size (US$ Mn) Forecast, by Drug Treatment, 2015–2025
Table 19: Latin America Myasthenia Gravis Market Size (US$ Mn) Forecast, by Rapid Immunotherapies, 2015–2025
Table 20: Middle East & Africa Myasthenia Gravis Market Size (US$ Mn) and Forecast, by Country, 2015–2025
Table 21: Middle East & Africa Myasthenia Gravis Market Size (US$ Mn) Forecast, by Treatment, 2015–2025
Table 22: Middle East & Africa Myasthenia Gravis Market Size (US$ Mn) Forecast, by Drug Treatment, 2015–2025
Table 23: Middle East & Africa Myasthenia Gravis Market Size (US$ Mn) Forecast, by Rapid Immunotherapies, 2015–2025

List of Figures

Figure 01: Global Myasthenia Gravis Market Size (US$ Mn) Forecast, 2015-2025
Figure 02: Market Value Share by Region (2016)
Figure 03: Market Value Share by Treatment (2016)
Figure 04: Market Value Share by Rapid Immunotherapies (2016)
Figure 05: Market Value Share by Drug Treatment (2016)
Figure 06: Global Myasthenia Gravis Market Value Share Analysis, Treatment, 2016 and 2025
Figure 07: Global Myasthenia Gravis Market Size (US$ Mn) and Y-o-Y Growth % Forecast, by Drug Treatment
Figure 08: Global Myasthenia Gravis Market Size (US$ Mn) and Y-o-Y Growth % Forecast, By Rapid Immunotherapies
Figure 09: Global Myasthenia Gravis Market Size (US$ Mn) and Y-o-Y Growth % Forecast, By Thymectomy
Figure 10: Global Myasthenia Gravis Market Size (US$ Mn) and Y-o-Y Growth % Forecast, By Cholinesterase Inhibitors
Figure 11: Global Myasthenia Gravis Market Size (US$ Mn) and Y-o-Y Growth % Forecast, By Chronic Immunomodulators
Figure 12: Global Myasthenia Gravis Market Size (US$ Mn) and Y-o-Y Growth % Forecast, By Monoclonal Antibodies
Figure 13: Global Myasthenia Gravis Market Size (US$ Mn) and Y-o-Y Growth % Forecast, By Plasmapheresis
Figure 14: Global Myasthenia Gravis Market Size (US$ Mn) and Y-o-Y Growth % Forecast, By Intravenous Immunoglobulin
Figure 15: Global Myasthenia Gravis Market Attractiveness Analysis, by treatment, 2017–2025
Figure 16: Global Myasthenia Gravis Market Value Share Analysis, by Region, 2016 and 2025
Figure 17: Myasthenia Gravis Market Attractiveness Analysis, by Region
Figure 18: North America Myasthenia Gravis Market Size (US$ Mn) Forecast, 2015–2025
Figure 19: North America Myasthenia Gravis Market Attractiveness Analysis, by Treatment, 2015–2025
Figure 20: North America Myasthenia Gravis Market Attractiveness Analysis, by Country
Figure 21: North America Myasthenia Gravis Market Value Share Analysis, by Country, 2016 and 2025
Figure 22: North America Myasthenia Gravis Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 23: Europe Myasthenia Gravis Market Size (US$ Mn) Forecast, 2015–2025
Figure 24:  Europe Myasthenia Gravis Market Attractiveness Analysis, by Treatment, 2017–2025
Figure 25: Europe Myasthenia Gravis Market Attractiveness Analysis, by Country, 2017-2025
Figure 26: Europe Myasthenia Gravis Market Value Share Analysis, by Country, 2016 and 2025
Figure 27: Europe Myasthenia Gravis Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 28: Asia Pacific Myasthenia Gravis Market Size (US$ Mn) Forecast, 2015–2025
Figure 29: Asia Pacific Myasthenia Gravis Market Attractiveness Analysis, by Treatment, 2015–2025
Figure 30: Asia Pacific Myasthenia Gravis Market Attractiveness Analysis, by Country
Figure 31: Asia Pacific Myasthenia Gravis Market Value Share Analysis, by Country, 2016 and 2025
Figure 32: Asia Pacific Myasthenia Gravis Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 33: Latin America Myasthenia Gravis Market Size (US$ Mn) Forecast, 2015–2025
Figure 34: Latin America Myasthenia Gravis Market Attractiveness Analysis, by Treatment, 2015–2025
Figure 35: Latin America Myasthenia Gravis Market Attractiveness Analysis, by Country/Sub-region
Figure 36: Latin America Myasthenia Gravis Market Value Share Analysis, by Country/Sub-region, 2016 and 2025
Figure 37: Latin America Myasthenia Gravis Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 38: Middle East & Africa Myasthenia Gravis Market Size (US$ Mn) Forecast, 2015–2025
Figure 39:  Middle East & Africa Myasthenia Gravis Market Attractiveness Analysis, by Treatment, 2015–2025
Figure 40: Middle East & Africa Myasthenia Gravis Market Attractiveness Analysis, by Country
Figure 41: Middle East & Africa Myasthenia Gravis Market Value Share Analysis, by Country, 2016 and 2025
Figure 42: Middle East & Africa Myasthenia Gravis Market Value Share Analysis, by Treatment, 2016 and 2025
Figure 43: Heat Map Analysis by Company (2016)
Figure 44: Alexion Pharmaceutical Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 45: Alexion Pharmaceutical Inc. Research & Development Expenses, 2015–2016
Figure 46: Alexion Pharmaceutical Inc. Breakdown of Net Sales, by Product, 2016
Figure 47: Alexion Pharmaceutical Inc. Breakdown of Net Sales, by Region, 2016
Figure 48: Avadel Pharmaceuticals, Plc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 49: Avadel Pharmaceuticals, Plc. Long-lived Assets (US$ Mn), by Geographic Region, 2016
Figure 50: Avadel Pharmaceuticals, Plc. Breakdown of Net Sales, by Product, 2016
Figure 51: Avadel Pharmaceuticals, Plc. Net Sales, by Region, 2016
Figure 52: CSL Behring Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
Figure 53: CSL Behring Research & Development Expenses, 2015–2016
Figure 54: CSL Behring Breakdown of Net Sales, by Product, 2016
Figure 55: CSL Behring Breakdown of Net Sales, by Region, 2016
Figure 56: Grifols, S.A. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 57: Grifols, S.A. Research & Development Expenses, 2014–2016
Figure 58: Grifols, S.A. Breakdown of Net Sales, by Business Segment, 2016
Figure 59: Grifols, S.A. Breakdown of Net Sales, by Region, 2016
Figure 60: Baxter International, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2016
Figure 61: Baxter International, Inc. Marketing and R&D Expenses, 2015–2016
Figure 62: Baxter International, Inc. Breakdown of Net Sales, by Product, 2016
Figure 63: Baxter International, Inc. Breakdown of Net Sales, by Region, 2016
Figure 64: Shire plc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 65: Shire plc. R&D and Marketing Expenses, 2014–2016
Figure 66: Shire plc. Breakdown of Net Sales, by Product, 2016
Figure 67: Shire plc. Breakdown of Net Sales, by Region, 2016
Figure 68: Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 69: Novartis AG Marketing & Sales, and R&D Expenses, 2015–2016
Figure 70: Novartis AG Breakdown of Net Sales, by Business Segment, 2016
Figure 71: Novartis AG Breakdown of Net Sales, by Region, 2016
Figure 72: F. Hoffmann-La Roche AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 73: F. Hoffmann-La Roche AG Marketing and R&D Expenses, 2015–2016
Figure 74: F. Hoffmann-La Roche AG Breakdown of Net Sales, by Business Division, 2016
Figure 75: F. Hoffmann-La Roche AG Breakdown of Net Sales, by Region, 2016
Figure 76: Takeda Pharmaceutical Company Limited Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 77: Takeda Pharmaceutical Company Limited Research and Development Expenses, 2015–2016
Figure 78: Takeda Pharmaceutical Company Limited Breakdown of Net Sales, by Business Segment, 2016
Figure 79: Takeda Pharmaceutical Company Limited Breakdown of Net Sales, by Region, 2016
Figure 80: Valeant Pharmaceuticals International, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 81: Valeant Pharmaceuticals International, Inc. Marketing and R&D Expenses, 2015–2016
Figure 82: Valeant Pharmaceuticals International, Inc. Breakdown of Net Sales, by Region, 2016
Figure 83: Valeant Pharmaceuticals International, Inc. Breakdown of Net Sales, by Business Segment, 2016